Amylyx Pharmaceuticals Announces First Patients Enroll in Open Label Extension of CENTAUR Phase 2 Clinical Trial of AMX0035 for Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis, ALS, is the most prevalent adult-onset progressive motor neuron disease, affecting more than 20,000 people in the U.S. and an estimated 450,000 people worldwide. ALS causes the progressive degeneration of motor neurons, resulting in rapidly progressing muscle weakness and atrophy that eventually leads to partial or total paralysis; on average, the disease is fatal within just three years from onset. There are currently just three therapies approved specifically for treating ALS—riluzole and the recently-approved edaravone.
About MGH Neurological Clinical Research Institute (NCRI)
Established in 1994 at the heart of Massachusetts General Hospital (MGH), the mission of the NCRI (www.massgeneral.org/ncri) is to accelerate translational research in neurological disorders through initiating and testing novel therapies. The NCRI is a premier academic Contract Research Organization (CRO) that leverages the vast disease knowledge of extraordinary physician-investigators to provide high quality clinical trials design and conduct of multicenter neurological trials. The NCRI serves as both the Coordinating Center and a clinical research site for the Northeast ALS Consortium (NEALS) (www.neals.org) a network of ALS specialists at more than 100 locations worldwide.
About The ALS Association
The ALS Association is the only national non-profit organization fighting Lou Gehrig’s Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure. For more information about The ALS Association, visit our website at www.alsa.org.
About ALS Finding a Cure®
ALS Finding A Cure® is dedicated to being a game changer in discovering a cure for this fatal disease. Founded in 2014 by noted philanthropist and Conair Founder and Chairman, Leandro (Lee) Rizzuto, as a tribute to Christie Rizzuto, Lee’s daughter-in-law who was diagnosed with ALS in 2009 at the age of 41, and under the leadership of Peter N. Foss and a team of renowned ALS researchers, ALS Finding A Cure® is focused on identifying the gaps in the scientific understanding of ALS that are preventing the development of a cure. The organization, a program of The Leandro P. Rizzuto Foundation, collaborates with a wide range of companies, ALS organizations, other disease research organizations, and ALS patients and families to ensure research efforts are non-duplicative, synergistic, and focused on the ultimate goal: finding a cure. For more information about ALS Finding a Cure®, visit http://www.alsfindingacure.org.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company currently developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company’s therapeutic, AMX0035, targets the neuroinflammation and nerve cell death that characterize these diseases. AMX0035 is a proprietary combination of existing compounds that have worked synergistically to prevent cell death and neurotoxic inflammation in multiple preclinical models. AMX0035 entered a Phase 2 clinical trial (CENTAUR) in ALS patients in June 2017. Learn more at: www.amylyx.com.
Source: Amylyx Pharmaceuticals, Inc.